| Patent application number | Description | Published |
|---|
| 20080292052 | Methods for Assisting Recovery of Damaged Brain and Spinal Cord and Treating Various Diseases Using Arrays of X-Ray Microplanar Beams - A method of assisting recovery of an injury site of the central nervous system (CNS) or treating a disease includes providing a therapeutic dose of X-ray radiation to a target volume through an array of parallel microplanar beams. The dose to treat CNS injury temporarily removes regeneration inhibitors from the irradiated site. Substantially unirradiated cells surviving between beams migrate to the in-beam portion and assist recovery. The dose may be staggered in fractions over sessions using angle-variable intersecting microbeam arrays (AVIMA). Additional doses are administered by varying the orientation of the beams. The method is enhanced by injecting stem cells into the injury site. One array or the AVIMA method is applied to ablate selected cells in a target volume associated with disease for palliative or curative effect. Atrial fibrillation is treated by irradiating the atrial wall to destroy myocardial cells while continuously rotating the subject. | 11-27-2008 |
| 20090062876 | Quantum dot labeled stem cells for use in providing pacemaker function - The present invention provides methods and compositions relating to the labeling of target cells with nanometer scale fluorescent semiconductors referred to as quantum dots (QDs). Specifically, a delivery system is disclosed based on the use of negatively charged QDs for delivery of a tracking fluorescent signal into the cytosol of target cells via a passive endocytosis-mediated delivery process. In a specific embodiment of the invention the target cell is a stem cell, preferably a mesenchymal stem cell (MSC). Such labeled MSCs provide a means for tracking the distribution and fate of MSCs that have been genetically engineered to express, for example, a hyperpolarization-activated cyclic nucleotide-gated (“HCN”) channel and administered to a subject to create a biological pacemaker. The invention is based on the discovery that MSCs can be tracked in vitro for up to at least 6 weeks. Additionally, QDs delivered in vivo can be tracked for up to at least 8 weeks, thereby permitting for the first time, the complete 3-D reconstruction of the locations of all MSCs following administration into a host. | 03-05-2009 |
| 20100047216 | COMPOSITIONS OF LATE PASSAGE MESENCHYMAL STEM CELLS (MSCS) - The present invention provides methods and compositions relating to the use of late passage mesenchymal stem cells (MSCs) for treatment of cardiac disorders. Such late passage MSCs may be administered to the myocardium of a subject for induction of native cardiomyoctye proliferation and repair of cardiac tissue. Additionally, the late passage MSCs may be genetically engineered to express a gene encoding a physiologically active protein of interest and/or may be incorporated with small molecules for delivery to adjacent target cells through gap junctions. The late passage MSCs of the invention may be used to provide biological pacemaker activity and/or provide a bypass bridge in the heart of a subject afflicted with a cardiac rhythm disorder. The biological pacemaker activity and/or bypass bridge may be provided to the subject either alone or in tandem with an electronic pacemaker. | 02-25-2010 |
| 20100049273 | USE OF LATE PASSAGE MESENCHYMAL STEM CELLS (MSCS) FOR TREATMENT OF CARDIAC RHYTHM DISORDERS - The present invention provides methods and compositions relating to the use of late passage mesenchymal stem cells (MSCs) for treatment of cardiac rhythm disorders. The late passage MSCs of the invention may be used to provide biological pacemaker activity and/or provide a bypass bridge in the heart of a subject afflicted with a cardiac rhythm disorder. The biological pacemaker activity and/or bypass bridge may be provided to the subject either alone or in tandem with an electronic pacemaker. | 02-25-2010 |
| 20100158805 | QUANTUM DOT LABELED STEM CELLS FOR USE IN CARDIAC REPAIR - The present invention provides methods and compositions relating to the labeling of target cells with quantum dots (QDs). Specifically, a delivery system is disclosed based on the use of negatively charged QDs for delivery of a tracking fluorescent signal into the cytosol of target cells via a passive endocytosis-mediated delivery process. In a specific embodiment of the invention the target cell is a stem cell, preferably a mesenchymal stem cell (MSC). Such labeled MSCs provide a means for tracking the distribution and fate of MSCs that have been administered to a subject to promote cardiac repair. The invention is based on the discovery that MSCs can be tracked in vitro for up to at least 6 weeks. Additionally, QDs delivered in vivo can be tracked for up to at least 8 weeks, thereby permitting for the first time, the complete 3-D reconstruction of the locations of all MSCs following administration into a host. | 06-24-2010 |
| 20100330050 | USE OF HUMAN STEM CELLS AND/OR FACTORS THEY PRODUCE TO PROMOTE ADULT MAMMALIAN CARDIAC REPAIR THROUGH CARDIOMYOCYTE CELL DIVISION - The present invention relates to methods and compositions for stimulating the proliferation of cardiomyocytes for enhancement of cardiac repair. The invention is based on the discovery that upon contact with stem cells, or conditioned media derived from said stem cells, terminally differentiated cardiomyocytes can be stimulated to enter the cell cycle. Additionally, scaffolds capable of attracting stem cells to the area of implantation have been shown to induce cardiomyocyte proliferation. The present invention further relates to the discovery that the Wnt-5A ligand, which binds to the frizzled receptor (fz), functions to stimulate cardiomyocyte proliferation. The methods and compositions of the invention may be used in the treatment of cardiac disorders including, but not limited to, myocardial dysfunction or infarction. The invention further relates to screening assays designed to identify compounds that modulate the proliferative activity of cardiomyocytes and the use of such compounds in the treatment of cardiac disorders. | 12-30-2010 |
| 20110034867 | MICROTHREAD DELIVERY SYSTEM - Compositions that include microthreads are provided. The compositions can be fully or partially encased in a sleeve along at least a portion of their length and can include biological cells and, optionally, therapeutic agents. Also provided are methods for using the compositions to repair or ameliorate damaged or defective tissue, including cardiovascular tissue (e.g., the myocardium). | 02-10-2011 |
| 20110041857 | FIBROBLAST DERIVED STEM CELLS - The present invention provides methods and compositions relating to the production of stem cells, derived from dedifferentiated fibroblasts, and the use of such stem cells for treatment of a variety of different disorders and conditions. The invention is based on the surprising discovery that a population of stem cells, capable of differentiating into a variety of different cell types, can be generated by culturing fibroblasts under selective culture conditions. | 02-24-2011 |
